Bausch Plus Lomb Corp.

Business Model and Scope

Bausch + Lomb is an eye-health company spanning consumer products, contact lenses, prescription pharmaceuticals, and surgical devices. Vision Care sells daily and reusable contact lenses, lens-care solutions, dry-eye drops, vitamins, and other over-the-counter products. Pharmaceuticals sells prescription treatments including MIEBO, Xiidra, Vyzulta, and Lotemax products. Surgical sells intraocular lenses, phacoemulsification and vitreoretinal equipment, instruments, and consumables used by ophthalmic surgeons.

The businesses share the eye-care channel but have different economics. Consumer products depend on brand, retail shelf space, manufacturing scale, and repeat purchase. Contact lenses require material science, fit, practitioner recommendation, and high-volume precision production. Pharmaceuticals require clinical evidence, regulatory approval, physician adoption, payer access, and rebates. Surgical systems place durable equipment in operating rooms and can create recurring demand for lenses, packs, and instruments, but recalls or weak equipment placement damage that stream.

Revenue reached $5.101 billion in 2025, up 6% from $4.791 billion in 2024 and 35% from $3.768 billion in 2022. Vision Care supplied $2.923 billion, or 57%; Pharmaceuticals $1.284 billion, or 25%; and Surgical $894 million, or 18%. Acquisitions and launches contributed materially, so the increase should not be read as purely organic. The top ten products and franchises produced 56% of revenue, up from 48% in 2023, increasing concentration around major brands.

Customers and Purchasing Decisions

Consumers buy lenses and eye-care products for clear vision, comfort, convenience, appearance, and confidence that a product touching the eye is safe. Daily disposable lenses trade higher recurring cost for hygiene and convenience. Lens wearers can switch brands after professional refitting, but comfort and prescription familiarity create friction. Retail eye drops and vitamins face lower switching costs and strong shelf competition.

Eye-care professionals are critical intermediaries. Optometrists recommend and fit contact lenses; ophthalmologists prescribe drugs and select surgical equipment and implants. They value clinical performance, predictable outcomes, training, product availability, and service. A surgeon using a platform and trained staff may prefer compatible consumables, but can switch if reliability deteriorates. The 2025 enVista intraocular-lens recall demonstrates that trust can transfer economics back to customers through lost sales, remediation, and weaker placement.

Pharmaceutical patients value symptom relief and tolerability, while insurers, pharmacy-benefit managers, and government programs influence whether the prescription is affordable. Gross-to-net discounts, rebates, chargebacks, copay support, and formulary placement separate list price from retained revenue. Consolidation among wholesalers, retail chains, and payer organizations increases their bargaining power.

Bausch + Lomb sells through about 4,200 commercial employees and independent distributors in roughly 100 countries. In the United States, products move through wholesalers, retailers, pharmacies, and professional practices. International distributors expand reach but retain margin and control local execution. The ultimate customer relationship is therefore shared among the company, clinician, payer, retailer, and distributor.

Profit Creation and Value Capture

Vision Care creates profit through repeat purchase, brand-supported pricing, and high utilization of specialized manufacturing. Once lens formulations and production lines are validated, volume can spread research, quality, and plant overhead. Consumer products add retail distribution and advertising costs but can reuse brands across categories. In 2025, Vision Care generated $849 million of segment profit on $2.923 billion of revenue, a 29% margin, compared with $808 million in 2024.

Pharmaceutical profit depends on protected or differentiated products retaining net price after payer deductions, manufacturing or royalty cost, promotion, and R&D. Xiidra and MIEBO expanded the dry-eye franchise, but acquisition price and license milestones are part of their economics. Pharmaceuticals generated $258 million of segment profit on $1.284 billion of revenue in 2025, a 20% margin. Profit grew only $2 million despite $75 million of revenue growth because gross-to-net pressure, selling and promotion, and R&D absorbed the increase.

Surgical profit should arise from installed equipment, high-value implants, and recurring procedure consumables. In 2025, revenue rose to $894 million, but segment profit fell from $44 million to $18 million, a 2% margin, primarily because of the voluntary recall of certain enVista lenses and higher acquisition-related selling cost. This is contrary evidence to the claim that installed systems automatically create attractive recurring profit. Quality and utilization determine whether the company or the clinician captures the value.

Total segment profit was $1.125 billion, but corporate costs of $679 million, intangible amortization of $258 million, and other expense of $75 million reduced operating income to $113 million. Interest expense was $421 million, producing a $317 million pre-tax loss and a $360 million net loss attributable to Bausch + Lomb. Customers receive vision and health benefits; clinicians, distributors, retailers, payers, employees, licensors, acquisition sellers, and creditors take claims. The segment franchise creates operating value, but debt and purchased intangibles prevent most of it from reaching common shareholders.

Industry Structure and Capital Cycle

Eye care is divided among global contact-lens manufacturers, consumer-health companies, branded and generic drug makers, surgical-device companies, and local distributors. Competitors include large diversified firms with comparable research budgets, manufacturing networks, practitioner relationships, and established brands. Competition turns on safety, clinical performance, comfort, convenience, innovation, practitioner training, formulary access, retail placement, service, price, and promotion.

Customers have different bargaining power. Individual lens wearers are fragmented, but can compare price and switch after refitting. Surgeons and practices have influence because their product decisions drive procedures and recurring consumables. Hospitals and buying groups can negotiate capital equipment. Payers and consolidated wholesalers exert strong pharmaceutical power through formularies, rebates, and channel access. Retail chains control shelf visibility for over-the-counter products.

Suppliers include chemical and polymer producers, precision equipment vendors, active pharmaceutical ingredient makers, contract manufacturers, logistics providers, licensors, and skilled plant labor. Bausch + Lomb operates manufacturing facilities in 11 countries and outsources the remainder. Internal plants protect process knowledge and supply, but create fixed cost and regulatory exposure. A qualified sole or limited source can gain leverage because changing a supplier may require validation and approval.

Substitutes include eyeglasses, refractive surgery, competing lenses, generic drugs, other mechanisms for dry eye or glaucoma, and alternative surgical implants and systems. Distribution depends on professional recommendation, direct sales, wholesalers, retailers, pharmacies, and country distributors. Financing matters because drug acquisitions, manufacturing lines, inventory, clinical studies, and surgical platforms consume cash before repeat sales develop.

Entry barriers are meaningful but product-specific: regulatory clearance, patents, clinical data, precision manufacturing, quality systems, brands, and clinician relationships. They do not prevent generic entry after loss of exclusivity or a rival device with superior outcomes. FDA, Health Canada, European, and other authorities regulate development, manufacturing, labeling, promotion, and post-market surveillance; payers can limit economics even after approval.

The capital cycle can destroy value through acquisition bidding and capacity expansion. Attractive dry-eye growth draws licensed drugs, promotions, and competing mechanisms. Contact-lens producers add specialized capacity slowly; temporary shortages may aid pricing, while overcapacity or retailer inventory corrections depress utilization. Surgical equipment placement can be subsidized to secure consumables. Durable profit comes from repeat demand and reliable clinical performance, not acquisition-driven revenue, temporary channel inventory, or underinvestment in quality.

Sources and Durability of Competitive Advantage

Bausch + Lomb's strongest asset is a coordinated eye-care distribution and professional network across consumer, prescription, and surgical categories. A global commercial team can discuss several products with the same clinicians, identify cross-selling opportunities, and support launches. Long-used brands reduce perceived safety risk for consumers and retailers. Manufacturing know-how in lenses, solutions, drugs, and surgical devices is specialized and regulated.

Contact-lens fit and comfort create practical switching costs; surgical equipment and training can create installed-base demand; patents and regulatory exclusivity can protect pharmaceuticals. Bausch + Lomb's presence in approximately 100 countries spreads development and brand costs. These mechanisms can retain value when supported by product reliability and appropriate pricing.

The evidence sets clear limits. Vision Care's 29% segment margin is attractive but sits before corporate and financing costs. Pharmaceutical revenue growth produced almost no incremental segment profit in 2025. Surgical margin fell to 2% after the enVista recall. Brands cannot compensate indefinitely for manufacturing or safety failures, and payer rebates can transfer protected-drug value away from the manufacturer.

Acquired products also divide the advantage with former owners and licensors. MIEBO may require about $88 million of additional sales milestones; Xiidra required a $1.750 billion upfront payment financed partly with expensive debt. The company owns the commercial relationship, but sellers and creditors captured much of the expected value in advance.

Operating System and Strategic Trade-offs

The operating system links research, regulatory work, precision manufacturing, quality assurance, practitioner education, direct sales, distributor management, reimbursement, and post-market monitoring. Contact lenses require high-volume consistency; pharmaceuticals require validated active ingredients and compliant promotion; surgical products require traceability, sterile supply, training, and rapid complaint response. Shared distribution does not make these production systems interchangeable.

Internal manufacturing improves control but increases asset specificity. At December 2025, net property, plant, and equipment was $1.762 billion and construction in progress $525 million. Inventory was $976 million, including $635 million of finished goods. Inventory supports a global product range, but forecast error, expiry, recalls, and product transitions can turn it into a cash loss. Inventory declined from $1.036 billion in 2024, contributing to 2025 operating cash improvement.

The enVista recall is an operating-system test. Surgical revenue still rose, but segment profit fell by $26 million. The economic response requires identifying affected lots, communicating with surgeons, replacing supply, correcting production, and restoring confidence. Faster revenue growth elsewhere does not neutralize a failure in a product implanted in patients.

Acquisitions increase integration demands. Xiidra, Blink, AcuFocus, and Trukera bring distinct supply agreements, salesforces, intangibles, and milestones. A useful dashboard would track plant yield, deviations, service levels, recalls, inventory days, gross-to-net deductions, practitioner retention, installed surgical systems, consumable pull-through, and product-level profit after royalties and amortization.

Financial Resilience

Bausch + Lomb ended 2025 with $397 million of cash and restricted cash and $5.107 billion of gross debt and other maturities. The contractual schedule in the filing showed $29 million due in 2026, $28 million in 2027, $1.914 billion in 2028, $23 million in 2029, $123 million in 2030, and $2.990 billion thereafter. A January 2, 2026 refinancing, completed before the filing cutoff, replaced $2.802 billion of term loans with a facility due January 2031; the published maturity table did not reflect that extension.

Refinancing reduces the 2028 concentration but leaves leverage and variable-rate exposure. The new term facility bears a SOFR-based rate plus 3.75%, or a base rate plus 2.75%. October 2028 secured notes used for the Xiidra acquisition bear 8.375%. Interest expense of $421 million exceeded operating income by more than three times in 2025. Creditors have a stronger current claim on business economics than common shareholders.

Operating cash was $283 million in 2025, $232 million in 2024, negative $17 million in 2023, and $345 million in 2022. The 2025 improvement came partly from payment and collection timing and lower inventory, not solely higher underlying profit. Investing cash use was $455 million, so operating cash did not fund investment spending. Debt issuance and repayment remained large.

A severe but plausible stress combines a product recall, payer pressure, retailer destocking, manufacturing cost inflation, and weaker credit markets. The company could reduce discretionary promotion and projects, but must preserve quality, supply, and regulatory compliance. With low cash relative to debt and negative net income, resilience depends on continuing access to secured financing and stable Vision Care cash.

Capital Allocation and Shareholder Outcomes

Capital allocation since the IPO has emphasized acquisitions, product launches, manufacturing investment, and refinancing rather than distributions. The Xiidra acquisition required a $1.750 billion upfront payment and associated financing. Blink and AcuFocus broadened consumer and surgical portfolios; Trukera added surgical products. Revenue expanded, but consolidated operating income was only $113 million in 2025 and attributable loss widened to $360 million.

The correct acquisition test is incremental cash after royalties, promotion, working capital, amortization, and financing. Pharmaceuticals added $75 million of 2025 revenue but only $2 million of segment profit. That one-year comparison does not establish lifetime return, but it contradicts a simple scale thesis. Surgical acquisitions also have not yet overcome recall and selling costs.

No dividends have been declared since the IPO, and debt covenants restrict distributions and other actions. Retaining cash is appropriate given leverage, but shareholders still bear acquisition and refinancing risk. Stock compensation and withholding payments create dilution or cash claims, though they are smaller than debt service.

Bausch Health Companies beneficially owned approximately 88% of outstanding shares at December 2025 and controls the company. Minority holders rely on a parent whose intended separation remained incomplete. Related-party and separation agreements, governance exemptions, and the parent's ability to elect directors can shape allocation. Operational value reaches public minority shareholders only after creditor claims and controller decisions.

Legal and Regulatory Exposure

Eye-health products face extensive premarket approval or clearance, good-manufacturing-practice inspections, labeling, promotion, adverse-event reporting, and recall authority. Regulators can stop production, require remediation, narrow indications, seize products, or mandate withdrawal. A quality failure can damage several categories because clinicians associate the corporate name with eye safety.

Pharmaceutical patents and exclusivity face generic and biosimilar challenge. Loss of exclusivity can cause rapid volume and price decline. Payer rebates, Medicaid rules, price-reporting, anti-kickback law, and promotional restrictions affect retained revenue. MIEBO, Xiidra, and other licensed products carry contractual milestones and royalty or supply obligations in addition to regulation.

Product liability is especially material for implanted lenses, surgical equipment, pharmaceuticals, and products used directly on the eye. Cybersecurity and privacy rules cover patient, clinician, and employee data. International operations add sanctions, anti-corruption, tariffs, currency, customs, and local approval risk.

Bausch Health's continued control creates legal and governance exposure through related-party arrangements, shared tax and separation obligations, and controlled-company exemptions. A failed or delayed separation may not change product demand, but it can constrain financing, strategic flexibility, and minority influence.

Conclusion, Uncertainties and Disconfirming Evidence

Bausch + Lomb creates customer value across a coherent clinical channel: repeat consumer and lens purchases, protected prescription products, and surgical systems supported by practitioner relationships and regulated manufacturing. Vision Care retains meaningful segment economics, and the distribution network can support new products. Yet consolidated profit is largely claimed by corporate cost, acquired-intangible amortization, and interest.

The adverse case is a reinforcing combination: payer discounts limit dry-eye returns, another quality event weakens surgical adoption, contact-lens manufacturing underutilizes new capacity, inventory consumes cash, and higher rates keep interest above operating income. Acquisition milestones and promotion would then compete with remediation and debt reduction. The controller could prioritize objectives that do not maximize minority per-share value.

The thesis would be invalidated by recurring recalls, sustained Surgical margins near current levels, Pharmaceutical revenue growth without cash contribution, operating cash that repeatedly fails to cover necessary investment, leverage remaining above the capacity of operating income, loss of critical product rights, or continued acquisition spending before prior deals earn their cost. Evidence of reliable manufacturing, restored surgical profitability, stronger pharmaceutical contribution after gross-to-net deductions, and internally funded debt reduction would strengthen it.

The evidence limitation is consequential: only four standalone Forms 10-K exist, all after the May 2022 IPO, so the retained record does not cover a full independent cycle or show how the present balance sheet performs through a prolonged downturn. Within that limited history, revenue growth is established, but durable shareholder profit is not. Bausch + Lomb has valuable eye-care assets; common shareholders receive the benefits only if operating reliability and acquisition returns outrun financing and controller claims.

Business quality does not by itself establish investment attractiveness; valuation depends on the price paid and the expectations embedded in it.